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The clustered regularly interspaced short palindromic repeats system has demonstrated
considerable advantages over other nuclease-based genome editing tools due to its
high accuracy, efficiency, and strong specificity. Given that cancer is caused by an
excessive accumulation of mutations that lead to the activation of oncogenes and
inactivation of tumor suppressor genes, the CRISPR/Cas9 system is a therapy of choice
for tumor genome editing and treatment. In defining its superior use, we have reviewed
the novel applications of the CRISPR genome editing tool in discovering, sorting,
and prioritizing targets for subsequent interventions, and passing different hurdles of
cancer treatment such as epigenetic alterations and drug resistance. Moreover, we have
reviewed the breakthroughs precipitated by the CRISPR system in the field of cancer
immunotherapy, such as identification of immune system-tumor interplay, production of
universal Chimeric Antigen Receptor T cells, inhibition of immune checkpoint inhibitors,
and Oncolytic Virotherapy. The existing challenges and limitations, as well as the
prospects of CRISPR based systems, are also discussed.
Keywords: CRISPR, cancer treatment, gene therapy, cancer immunotherapy, CAR T cell therapy, genome-wide
screening assays, oncolytic virotherapy
INTRODUCTION
In recent years, various genetic manipulation techniques have been developed which involve
DNA repair mechanisms that incorporate site-specific modifications into a cell’s genome. These
techniques have made diverse genome alterations in a site-specific manner possible, as they are
able to edit tumor cells’ genome to induce apoptosis, reduce drug resistance, and restore mutant
genes. They also can be employed in immune system genetic manipulation to potentiate antitumor
immune responses (1–4). Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR)
is a novel mammalian cells’ genome editing technique derived from archaeal and bacterial antiviral
defense systems. Due to its exceptional potential and efficacy, this platform has defined a new
era, tipping the balance of cancer treatment in favor of genetic manipulation of the tumor
and immune cells. CRISPR is preferentially exploited to interrogate various genes and signaling
pathways’ functions, leading to the discovery of new therapeutic targets. In this review, we will
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discuss the CRISPR technique and explore its recent applications
in discovering new targets in cancer therapy and overcoming
different hurdles of cancer treatment, such as oncogenes,
epigenetic dysregulations, and drug resistance. We will also
dissect its redemptive potential in immunotherapy. The subtitles
that will be discussed later in this review are shown in Figure 1.
GENOME EDITING TECHNIQUES: ZFNs,
TALENs, AND CRISPR
Up until now, three nuclease-based systems have been developed
with ubiquitous genome editing applications and with the
capacity to be engineered for specific sequence targeting.
Zinc Finger Nucleases (ZFNs) are constructed by fusing zinc
finger protein motifs with the DNA cleavage domain of FOK1
endonuclease. Zinc fingers are small protein motifs that can bind
in the major groove of DNA in a sequence-specific manner.
Multiple zinc finger modules can be assembled into a more
massive complex to achieve higher specificity. As FOK1 needs
homodimerization at the target site to cleave DNA, two separate
zinc finger modules possessing adjacent target sites (Figure 2A)
are incorporated. Generally, ZFNs possesses the potential to
target sequences with 9–18 bp length (5–7).
Transcription Activator-Like Effector Nuclease (TALEN) is
another nuclease-based system similar to ZFN in many aspects.
TALENs are constructed by the chimeric fusion of the FOK1
cleavage domain to the complex of TALE DNA-binding modules.
Each module is comprised of 34–35 amino acids with the ability
to recognize a single base pair on the plus side. These TALE
proteins, which were first discovered in Xanthomonas bacteria,
can be designed to target 7–34 bp-long DNA targets (Figure 2A)
(8–10).
The third system, CRISPR/Cas, was first introduced by Cong
et al. and Mali et al. as a mammalian cell genome editing platform
(11–13). This discovery has led to dramatic improvements in
genetic manipulation specificity and efficacy. Moreover, it has
expanded the application spectrum beyond mere genome editing,
and new prospects of therapeutic and research purposes are being
explored (14–17).
CRISPR/Cas constitute adoptive immunity against
bacteriophages, transposable elements, and plasmids in Bacteria
and Archaea. Upon pathogen invasion, these organisms insert
segments of the invader genetic material into the CRISPR
loci as new spacers within two repeat sequences. In cases of
future invasions, these loci are transcribed into pre-crRNA and
subsequently processed by Cas and other cellular agents into its
mature form, CRISPR RNA (crRNA) (18–20). After that, the
(crRNA)/Cas protein(s) complex detects mobile genetic elements
with sequence specificity primarily arising from Watson-Crick
base pairing between crRNA and target DNA (21).
There are two major classes and several types of CRISPR
systems based on differences in components and mechanisms of
action. In contrast to other classes, which rely on many effector
proteins for RNA-guided target cleavage, the class 2 system relies
on only one RNA guided endonuclease (Cas9 in type2 and Cpf1
in type5), turning it into a more straight-forward genetic-altering
device. Thus, researchers have widely used this class of CRISPR
system (14, 19–21).
CRISPR/Cas9 is the most extensively used CRISPR system
in genome editing techniques. This system employs Cas9 as its
RNA-guided endonuclease and crRNA as a guiding RNA, as well
as trans-activating CRISPR RNA (tracrRNA). tracrRNA is a non-
coding RNA and is critical for crRNA processing, Cas9 binding,
and target DNA breaking (Figures 2B,C) (in the type5 CRISPR
system, Cpf1 can detect and cleave the target DNA independently
of tracrRNA) (22–24).
Catalytically inactivated Cas9, dCas9, has many applications
beyond genome editing. As dCas9 cannot break DNA strands, it
is used as a sequence-specific DNA binding element. Through
binding different effector parts to dCas9, it can be used
as a transcription inhibitor or activator or even epigenetic
modulator (16). These applications and some other applications
are summarized in Figure 3.
CRISPR Versus ZFN and TALEN
CRISPR has demonstrated considerable advantages over ZFNs
and TALENs as it functions through DNA-RNA interaction.
Since ZFN and TALEN rely on protein-DNA interaction for their
sequence specificity, targeting a new site requires engineering a
new protein, hence constraining these tools’ implementation in
high-throughput applications. Additionally, the high molecular
weights of these proteins in correspondence to the length of
the sequence they target hinders multi-targeting during a single
process of genetic engineering, which is mainly due to the genetic
delivery limitations to the host and the metabolic burden they
impose on the target cell (25). In contrast, the CRISPR system
can be retargeted to a new site only by changing the guide
RNA sequence (4, 21). Moreover, multiple site-specific genetic
alterations are possible through the delivery of a single form
of Cas and multiple sgRNAs requiring fewer macromolecules
than multiple ZFNs and TALENs, which in turn results in
lower cellular toxicity. Besides, some have declared that CRISPR
possesses higher genome editing efficiency relative to ZFNs and
TALENs (11, 26, 27).
CRISPR/Cas AND TUMOR CELL
MANIPULATION
Characterizing and targeting genes responsible for tumorigenesis
and cancer progression remains crucial yet challenging.
Alterations in regulations of these genes, dubbed as oncogenes
and tumor suppressors, mediate resistance to therapy and
cancer progression. The CRISPR/Cas system has been exploited
for discovering and introducing such genes and their cognate
pathways as novel targets and has served as a powerful tool for
cancer gene therapy.
Gene Therapy via CRISPR/Cas
The excessive accumulation of specific mutations leads to
biological hallmarks of a malignant phenotype (28). Through
gene therapy, CRISPR/Cas9 technology is applicable in
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FIGURE 1 | Applications of CRISPR technology in multiple aspects of cancer treatment.
oncogenes’ inactivation or restoration of tumor suppressors and
apoptotic and immune-stimulatory functions.
A common characteristic of many tumor cells is a mutation in
tumor protein 53 (TP53 in human or TrP53 in mice). This gene
encodes the tumor suppressor protein p53, which is responsible
for halting cell proliferation in response to internal stress and
abnormality inputs (29). Almost half of human malignancies are
harboring an altered form of TP53 (2). Albers et al. showed that
CRISPR/Cas9-mediated inactivation of Transformation Related
Protein 53 (TrP53) and expression of oncogene H-Ras led to
cellular transformation and tumor formation in a xenograft
model (30).
Restoring the mutated TP53 to its wild type function using
various compounds can induce apoptosis and senescence in
tumor cells. Chira et al. envisioned a novel Tp53 therapeutic
concept, capable of replacing the entire mutant locus of TP53
(∼20.5 kb in length) with its functional cDNA version through
homologous recombination. This recombination required the
expression of two sgRNAs (single guide RNA comprising crRNA
and tracrRNA fusion) binding to upstream and downstream
flanking sites of the TP53 mutant locus. They designed a hybrid of
an Adeno-Associated Virus and a bacterioPhage (AAVP) directed
to tumor cells. Hence, the design increased the specificity,
and it could also possess an inducible functionally through
the administration of a simple antibiotic like doxycycline. The
intravenous administration of this therapeutic vector yielded
limited side effects and increased distribution, leading to
sustained expression of p53 and tumor regression even in distant
metastatic tumor sites (2).
Human Estrogen Receptor 2 (HER2) gene is a well-known
oncogene and is over-expressed in some cancers, such as
breast cancer, serving as a therapeutic target for Herceptin
(Trastuzumab). As an alternative, Wang et al. utilized a novel
strategy to target the oncogene HER2 with the CRISPR/Cas9
system. Co-expression of Cas9 and three sgRNAs targeting
HER2 exons 5, 10, and 12 significantly reduced cell growth and
tumorigenicity in Her2-positive breast cancer cells (31). One
advantage of employing CRISPR/Cas9-mediated HER2 down-
regulation over conventional therapeutics such as monoclonal
antibodies (mAbs) is the simplicity of designing new guide
RNAs for targeting new mutations in the case of resistance.
The development of conventional therapeutics would, on the
other hand, require a new drug discovery program, which is a
time-consuming and laborious practice.
Epidermal Growth Factor Receptor (EGFR) is a glycoprotein
anchored to the cell’s membrane and has an intracellular tyrosine
kinase domain. Constitutive tyrosine kinase activation due to
genetic mutation causes cancer formation and progression.
Although Tyrosine Kinase Inhibitors (TKIs) have been the
therapeutic choice for EGFR-expressing malignancies, resistance
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FIGURE 2 | ZFNs, TALENs, and CRISPR-based genome editing. (A) ZFNs and TALENs are nucleases that operate based on protein-DNA interactions. Assembling
Zinc Finger Motifs (ZFMs) and TALEs into larger complexes increases specificity. (B) CRISPR/Cas9 binds to DNA under the guidance of single guide RNA (sgRNA).
sgRNA is a chimeric RNA constructed by fusing crRNA and tracrRNA to simplify the guidance system. As a result, Cas9-sgRNA is the most extensively used system
in CRISPR based applications (23). For DNA recognition, many CRISPR systems also need Protospacer Adjacent Motif sequence (PAM) adjacent to the crRNA
target site. PAM sequences are specific to each type of nuclease (e.g., NGG sequence is specific to SpCas) (21, 198). (C) Double-Stranded Breaks (DSBs) created
by Cas9 in DNA structure activate two DNA repair pathways: Non-Homologous End Joining (NHEJ) and Homology-Directed Repair pathways (HDR). NHEJ results in
random insertions or deletions at the target site, so it involves knocking out genes in CRISPR-based applications. HDR is a precise pathway that repairs target DNA
breakage by using a homologous donor DNA. This pathway takes part in techniques that need more precise genome editing, like insertion or deletion of the desired
DNA fragment (199, 200).
against these medications develops within 2 years. Huibin
et al. proposed a molecular surgery using the CRISPR
system to repair the mutated EGFR using the CRISPR/Cas9
nickase platform. Alternatively, this strategy would halt its
activity by introducing a stop codon or an indel (random
insertions and deletions) through HDR and NHEJ, respectively
(32). This approach offers personalized gene therapy for
disease-causing genetic abnormalities, which can be coupled
with traditional therapeutic strategies, including surgeries
and radiotherapy.
One of the main approaches to cancer cell therapy is knocking
out genes responsible for inducing drug resistance. NFE2L2
gene [i.e., encodes Nuclear Factor Erythroid 2-Related Factor
(NRF2)] is up-regulated under various conditions, such as
oxidative or electrophilic stresses. These are consequences
of chemotherapeutic drug administration as well. NRF2
targets numerous genes encoding GSH mediators, antioxidant
proteins, and efflux pumps and induces cells’ resistance against
chemotherapy (33). Bialk et al. exploited CRISPR/Cas9 to knock
out the NRF2 gene in chemo-resistant lung cancer cells. They
reported restored effectiveness of anticancer drugs cisplatin,
carboplatin, and vinorelbine post-gene editing (34). Therefore,
the synergistic effects of combining gene edition and standard
therapeutic options such as chemotherapy may address drug
resistance-mediated refraction or relapse of the disease.
It is now known that epigenetic mechanisms play a critical role
in different cancers’ formation and progression (35). Recently,
the CRISPR/Cas9 system has shed light on the underlying
epigenetic irregularities and rendered researchers able to target
these irregularities using the CRISPR/Cas9 platform. Wang
et al. (36) targeted granulin (GRN), a liver cancer stem cell
marker, epigenetically using the CRISPR/Cas9 system. The
system consisted of C-terminus of the catalytically inactive dCas9
fused to three epigenetic suppressor domains: DNMT3a, histone
3 K27 methyltransferase EZH2, and heterochromatin binding
suppressor KRAB. The group then designed gRNAs specific to
the GRN promoter. Epigenetic targeting of GRN decreased tumor
cell growth compared with the random gRNA control and dCas9
control groups (36–38), thus introducing a powerful epigenetic
tool for oncogenes’ inhibition.
Moreover, some viruses can cause malignant phenotypes in
cells by inserting oncogenes into the cell genome. The CRISPR
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FIGURE 3 | dCas applications: beyond genome editing. (A) dCas9-KRAB has been engineered by fusing the KRAB transcription repressor domain to dCas9 (201).
(B) VP64, as a transcription activator, has been fused to dCas9 to activate a specific gene’s transcription (151, 152, 202, 203). (C) Recruiting multiple transcriptional
activators shows synergistic effects that have led to engineering many systems, such as VPR by in-tandem fusing of both p65 and Rta to VP64 (204). (D) SunTag is
a repeating protein-peptide array that recruits multiple antibody-fusion proteins. Protein domains, such as transcriptional activating or epigenetic modulating
domains, can be recruited by antibody-mediated binding to SunTag, which is fused with dCas (205, 206). (E) RNA aptamers (e.g., MS2, com, PP7) can be fused
with sgRNA to create a scaffold RNA (scRNA) that can recruit RNA-binding proteins (RBPs, e.g., MCP, Com, PCP). Fusing each RBP to the effector protein has
enabled gene activation, repression, or even simultaneous activation and repression in one cell (207). (F) In the synergistic activation mediator (SAM) system,
effectors are recruited by both dCas and scRNA (208). (G) Epigenetic modifying enzymes like P300 and LSD1 can be fused with dCas and alter cells’ epigenomic
features. These alterations were locus-specific epigenetic editing, including histone modifications and DNA methylations (205, 209, 210).
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system can be used against these virus-encoded oncogenes as
well. The most famous example is the human papillomavirus,
which is a primary causative agent for cervical cancer (39).
Hsu et al. targeted E6 and E7 HPV-encoded oncogenes with
CRISPR/Cas9 in patient-derived xenografts of HPV16 + anal
tumors in immunodeficient mice and showed growth inhibition
in tumor cells (40). CRISPR/Cas9 also induced proliferation
arrest and decreased viral load in patient-derived cells suffering
from Burkitt’s lymphoma with latent Epstein-Barr virus infection
(41). Based on these findings, CRISPR/Cas9 could be a promising
therapeutic approach for the treatment of viral infection-
related cancers.
As mentioned before, current CRISPR-based systems create
DSBs which induce cellular DNA repair pathways, causing
indels at the target locus. However, most diseases, including
cancers, are caused by several point mutations, and there is a
growing need for more efficient point mutation corrector tools.
Therefore, novel Cas9 variants have been introduced that convert
one base to another rather than creating DSBs. Accordingly,
Komor et al. conjugated cytidine deaminase enzymes with
dCas9 to convert a single base to another one (42). Their
designed Base Editor (BE) was able to convert C to T to correct
the p53 Tyr163Cys mutation that is associated with a variety
of cancers (43). Following the same approach, Kuscu et al.
introduced the CRISPR-STOP approach to create stop codons
by converting single bases using BEs previously introduced
by Komor et al. (44). Although the CRISPR-STOP approach
has fewer potential sgRNAs for a target gene than wild type
Cas9, introducing early stop codons is an efficient and safer
gene-silencing approach.
Prognostic and Predictive Biomarkers
Identification via CRISPR/Cas
Cancer biomarker discovery has emerged as an exciting area
of research in recent years, mainly due to advancements in
investigational screening tools for molecular level signatures,
such as genomic-based alterations. Biomarkers, which are
objectively measured and assessed features as an indicator of
a biological status or process, can play a pivotal role in a
patient’s outcome. Prognostic and predictive biomarkers refer to
biological characteristics that give information on the possible
course of cancer and the patient’s overall outcome irrespective
of the therapy and predict the potential therapeutic outcome
of a targeted treatment. The CRISPR/Cas platform can serve
as a valuable tool to identify these biomarkers though assessing
genetic or epigenetic changes within the tumor tissue (45, 46).
Cluster of Differentiation 44 (CD44) is a cell surface molecule
that interacts with hyaluronic acid (HA) in the extracellular
matrix. This interaction activates the mitogen-activated protein
kinases (MAPK) and PI3 kinases/akt pathways in the act
of oncogenic pathways (47, 48). Studies have revealed that
CD44 binds to P-glycoprotein (P-gp), which is encoded by
the ABCB1 gene and acts as a drug efflux pump (49). Hence,
its overexpression leads to resistance against chemotherapeutic
drugs such as vinblastine, doxorubicin, and paclitaxel in
osteosarcoma cells (50, 51). Xiaoa et al. used CRISPR/Cas9 to
knock out CD44 in drug-resistant cell lines. P-gp levels were
decreased as a consequence of CD44 knockout. CD44 knockout
diminished resistance to doxorubicin in osteosarcoma cells (52).
This study revealed that CD44 expression could serve as a
predictor for overall survival and chemotherapy response and
shed light on its role in tumor migration and tumorigenesis.
The Wnt-signaling pathway is considered as a pathway that
initially drives cells’ self-renewal in colorectal tumors (53).
Mutations in this pathway induce the pathway to be constitutively
active and provoke drug resistance. Furthermore, TIAM1, which
encodes a guanine nucleotide exchange factor specific to Rac1,
is a responsive gene to the Wnt signaling pathway and is
overexpressed in human colon cancer (54). Izumi et al. generated
xenograft mouse models with stable knockdown of TIAM1 using
CRISPR/Cas9 and subsequently treated them with 5-fluorouracil
(5-FU). TIAM1 knocked-down cells were more sensitive to 5-FU.
Also, the tumor size and weight notably diminished compared
to the controls. This study revealed the correlation between
TIAM1 overexpression in CRC cells and also cancer-associated
fibroblasts with drug resistance, serving as a predictive tool, and
introduced this molecule as a potential therapeutic target to
reverse drug resistance (55).
Qian et al. evaluated the effects of targeted DERARE
methylation on leukemogenesis. Distal Element Multiple
Retinoic Acid Response Element (DERARE) is a specific Cis-
Regulatory Element (CRE) that maintains the homeostasis
between self-renewal and multi-lineage differentiation. This
effect is due to the regulation of Hoxb cluster genes in a
methylation-dependent manner, which prevents leukemogenesis.
The CRISPR/Cas9 epigenetic editing tool employed in this study
was constructed by fusing the DNA methyltransferase 3A
(DNMT3A) catalytic domain to the C terminus of deactivated
Cas9 (dCas9). In this fusion, there was a short linker enabling
DNA methylation adjacent to the single guide RNA (sgRNA)
binding site on human DERARE (56). The group infected
human AML cell lines carrying the DNMT3A mutation via the
lentiviral vector and observed a remarkable reduction in colony
size and number in DNMT3A-dCAS9-treated AML cells (57).
Their research proposes DNA methylation patterns on DERARE
as a screening protocol for drug selection and implementing
personalized therapeutic approaches.
MicroRNAs (miRNAs) are small, non-coding RNA molecules
that play a role in cancer pathogenesis. There are different
miRNAs implicated in all stages of cancer functioning as
oncogenes or, conversely, as tumor suppressors. Hence assessing
their upregulation and downregulation could be a potent tool
to assess cancer progression (58). For example, a miRNA
that is overexpressed in hepatocellular carcinoma cells is
miR 3188. Zhou et al. demonstrated that this overexpression
induces tumor formation and progression, resulting in poor
clinical outcomes. Zhou and colleagues reported suppressed
cell growth, colony formation, cell cycle progression, and
increased apoptosis through CRISPR/Cas9-mediated miR-3188
knockout in cells (59), and proposed miR-3188 as a potent
therapeutic target and also as a biomarker for early detection
of HBV-related hepatocarcinogenesis among patients with a
family history of HCC.
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Identifying Novel Targets and
Deciphering Drug Resistance via
CRISPR/Cas
CRISPR/Cas9 is a potent genome editing tool for discovering
novel pathways and targets for cancer treatment and also
unraveling the mechanisms responsible for inducing drug
resistance and genes underlying these phenomena. CRISPR has
an essential advantage over other genome editing technics (e.g.,
ZFNs and TALENs) because it can be easily retargeted to another
locus in the genome by changing sgRNA design. Therefore, it
is possible to knock out different genes with CRISPR/Cas9 in
order to make explicit their role in cancer cell proliferation,
survival, and metastasis, and also to dissect their contribution
to developing drug resistance. Herein, we will review the results
of some recent studies deploying this approach using the
CRISPR/Cas9 genome -editing tool.
Feng et al. carried out an intervention using CRISPR/Cas9 to
knock out CDK11B in osteosarcoma cells. Inhibiting CDK11B
expression decreased cells’ viability and their migratory and
invasive activity. This study revealed the CDK11B role in cancer
pathogenesis and proposed its targeting as a potential approach
in augmenting osteosarcoma patients’ survival (60).
Urokinase Plasminogen Activator (uPA) binds to its
receptor (uPAR), which is encoded by the PLAUR gene. Their
interaction gives rise to extracellular matrix remodeling and
subsequent cell adhesion, migration, proliferation, and survival
via various signaling pathways (61, 62). Wang et al. revealed
that uPAR knockout by CRISPR/Cas9 reduces resistance to
chemotherapeutical drugs such as 5-FU, cisplatin, docetaxel, and
doxorubicin (63). Hence, this proves the uPA/uPAR pathway as
a potential target for intervention by other agents as well.
G-Protein-Coupled Receptor (GPCR) constitutes 40% of all
drug targets approved by the FDA. GPRC5a, which encodes the
G-Protein-Coupled Receptor family C, member 5, group A, also
named retinoic acid-inducible 3 (RAI3), is overexpressed in a
variety of cancers, including pancreas cancer (64, 65), which
makes it a potential biomarker for early diagnosis of cancer.
Liu et al. investigated the resistance of GPRC5a-knockout cells
against commonly used chemotherapeutic drugs such as 5-FU,
gemcitabine, and oxaliplatin. The group observed suppressed
resistance in GPRC5a knockout cells compared with wild type
cells using the EC50 (Concentration for 50% of maximal effect)
assay (66). Targeting this signaling pathway, thus, appears to be
an exciting area of further research.
KRAS is the most frequently mutated proto-oncogene in
cancer cells, and its pharmacological targeting has remained
challenging in cancer therapy (67). Since activating mutations
in KRAS are a hallmark of pancreatic ductal adenocarcinoma
(PDAC), CRISPR/Cas was employed in a study to model
complete KRAS inhibition and predict resistance mechanisms
in a subset of human and mouse PDAC cells. This study
showed the merit of KRAS-directed therapies in reducing in vitro
proliferation and in vivo tumorigenic growth and revealed KRAS’
role in balancing proliferation and metastasis in tumor cells. This
study also recommended PI3K pathway activation as a potential
resistance mechanism in KRAS knocked-out cells and suggested
simultaneous PI3K and KRAS inhibition as a therapeutic strategy
for PDAC (68).
The N-Myc oncoprotein, which is overexpressed in a
fraction of different types of prostate cancers (69–71), possesses
identified functions in tumor progression (70, 72). Yin et al.
reported that the N-Myc-regulated DNA Damage Response
(DDR) pathway (N-Myc/miR-421/ATM) is associated with
tumor progression and hormonal therapy resistance, such as
enzalutamide resistance. N-Myc overexpression cooperates with
EZH2 to suppress miR-421. This suppression leads to ATM
up-regulation, resulting in enzalutamide resistance. Yin and
colleagues knocked out ATM via the CRISPR/Cas9 genome
editing tool and detected re-sensitized prostate cancer cells (73).
Apolipoprotein B mRNA editing the enzyme catalytic
polypeptide-like (APOBEC) enzyme family is involved in genetic
instability and heterogeneity. APOBEC enzyme family derived
DNA mutagenesis patterns have been detected in different types
of cancers (74), including breast (75), bladder, cervix, head
and neck, lung cancers (76), and gliomas (77). Schmitt et al.
investigated the role of APOBEC3B in glioma cells’ resistance
to temozolomide by determining the caspase 3/7 activity. They
knocked down APOBEC3B using CRISPER/Cas9 and observed
higher sensitivity toward temozolomide relative to the control
cells (77).
miR-21 is a miRNA overexpressed in cancers. Huo et al.
hampered its expression via indels introduced by CRISPR/Cas9.
The group reported the inhibition of cell proliferation, migration,
and invasion in ovarian cancer cells. The hampered expression of
miR-21 was associated with higher drug sensitivity and decreased
Epithelial to Mesenchymal Transition (EMT), revealing its role in




CRISPR/Cas genome-scale knockout screening refers to the
process of sgRNA-mediated disruption of genes’ functionalities
aiming to discover novel genes and pathways underlying various
phenotypes and biological processes, including tumorigenesis
and drug resistance in cancer, and also their potential as
therapeutic targets (80, 81). Numerous studies have employed
genome-wide knockout libraries (GeCKO) which contain a
multitude of sgRNAs against a defined set of genes involved in
cancer. sgRNAs in the cells affect their competence for viability
during the proliferation. The enrichment or depletion of these
sgRNAs thereupon reveals the genes responsible for the cognate
phenotype (82–88).
Among the pioneering groups to both develop and implement
GeCKO (15, 89), Shalem et al. unraveled novel genes responsible
for the development of resistance to Vemurafenib (PLX) (i.e.,
a BRAF protein kinase inhibitor) in melanoma. Cells were
transduced with a pool of lentiviruses each carrying Cas9 and a
sgRNA. Thereafter, cells underwent PLX selection. The enriched
sgRNAs in viable cells were then sequenced and their target
genes, whose loss of function contributed to the development
of resistance, were revealed (15). Decoding the mechanisms
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underlying resistance to drugs can introduce novel predictive
biomarkers and even novel targets.
In a similar study, Manguso et al. unraveled the mechanisms
underlying the resistance to PD-1/PD-L1 inhibition treatment
using a library of lenti-vectors with sgRNAs targeting 2368
murine genes. This study revealed Ptpn2 as a potential target
to revert PD-L1 immunotherapy resistance since its knockout
was associated with increased sensitivity to immunotherapy (90).
IRF4, STAT3, SOS1, and GRB2 genes’ knockout in ALK + ALCL
cells also attenuated PD-L1 expression and undermined PD-L1
mediated T cells and NK cells suppression (91).
Genes responsible for the resistance to Bortezomib (BTZ)
in Multiple Myeloma have been determined by conducting a
genome-scale positive selection assay. Multiple myeloma cells
transduced with sgRNA-carrying lentiviruses were cultured in
the presence of BTZ at its lethal dose. The inactivated genes
in survived cells were identified based on the enriched sgRNAs
sequencing, and proteasome regulatory subunit PSMC6 was
proven to be the only gene that granted resistance to BTZ
reproducibly. Therefore, PSMC6 emerged to be a promising
predictive biomarker and also a novel target (92).
This strategy has also been employed to discover the
mechanism of action of Immunomodulatory imide drugs
(IMiDs), including mediating pomalidomide and lenalidomide.
Liu et al. explored the mechanism responsible for the
susceptibility of multiple myeloma cell lines to IMiDs by
loss-of-function genome-wide screening. The team found CRBN
regulation mediated by CSNs as the major factor determining
multiple myeloma cells’ sensitivity to IMiDs (93).
CRISPR genome-wide screening has also proven to be
beneficial in novel target identification. A dropout screen on
AML cell lines revealed that the sgRNA-mediated knockout of
KAT2A hampers AML cell lines’ growth. The same outcome was
observed when AML cell lines were treated with MB-3, a KAT2A
inhibitor. Therefore, since KAT2A is not an essential gene for
hematopoietic progenitor cells, its inhibition is proposed as a
novel anti-AML therapeutic strategy and MB-3 as a potential
medication for AML (94).
Another genome-wide negative selection screen on AML
employed mouse lentivirus-based GeCKO v2 library. Among
the genes dispensable for human hematopoiesis, the mRNA
de-capping enzyme scavenger (DCPS) appeared to be essential
for AML cell survival. Its inhibitor, RG3039, exhibited anti-
leukemia effects in human AML xenograft models, sparking
its combination with other drugs as a potential therapeutic
approach (95).
CRISPR/Cas has surpassed RNA interference (RNAi)
technology in building genome-wide knockout libraries due
to having a lower rate of off-targets and also introducing loss-
of-function mutations into the gene’s sequence as opposed to
RNAi which only yields the gene’s partial suppression in the
majority of cases (15, 81, 96). However, CRISPR/Cas imposes
some limitations; first, during drop-out screenings, CRISPR/Cas
has shown conditional false-positive results in cancers with
aneuploidy. Second, genomic regions with multiple copy
numbers, including non-expressed genes, are subject to excessive
double-strand breaks (DSBs). DSBs in turn lead to substantial
DNA damage and subsequently induce apoptosis. Hence,
sgRNAs targeting non-expressed genes should be excluded from
the libraries. Third, sgRNAs are conventionally designed to target
5’ exon. However, false-negative results have been attributed to
genes with initiation points in other exons as well, signifying the
effect of sgRNA positioning in the accuracy of the outcomes (97).
CRISPR AND IMMUNOTHERAPY
It has been established that evading immune destruction is one
of the hallmarks of cancer. Tumor cells can inhibit immune
effector cells or cause immune tolerance through the secretion
of extrinsic factors affecting the tumor microenvironment (TME)
(98). Among all the immune system members present at
TME, macrophages and T cells are the most distorted. Tumor-
associated macrophages (TAMs) support tumorigenesis and
metastasis and inhibit antitumor responses by releasing EGF,
IL-6, TNF, MMPs, VEGFA, TGF-β, IL-10, and PD-L1 (98, 99).
In addition, T cells’ anti-tumor activity and metabolic state
is disrupted by the immune-modulatory cytokines present in
the TME and the immune checkpoint inhibitors such as PD-
1 and CTLA-4 (99, 100). Accordingly, a study by Chung et al.
on 11 breast cancer cases revealed that the presence of M2
macrophages in the TME was correlated with T cell exhaustion
(101). Therefore, the state of TME strongly affects the patients’
prognosis. Hence, identifying the mechanisms underlying the
tumorigenic characteristics of interactions between immune
suppressive cells and tumors can reveal novel therapeutic
targets for developing antagonists, such as mAbs, and immuno-
modulatory drugs intervention.
Another approach is to fortify already existing immune
responses or develop new ones through bypassing their
dependence on the robust and intact immune system, which, as
explained before, had transformed into a non-functional state
(102). Adoptive T cell immunotherapy of cancer has recently
proven its potential in numerous clinical trials, yet it still suffers
from various predicaments (103).
CRISPR/Cas-mediated genetic manipulation has strived to
address some of the challenges mentioned above regarding
immune system misfunctioning from various prospects, some of
which are discussed below.
Novel Immune System-Tumor Interplay
Identification via CRISPR/Cas
TME is composed of tumor cells, stromal cells, and immune cells,
and the interaction among these cells affects tumor progression.
Stimulants present in the TME, such as cytokines, chemokines,
and growth factors, determine the polarization of macrophages
and their differentiation toward M1 or M2 subtypes. M1
macrophages are able to: (i) release pro-inflammatory cytokines
such as IL-12, IFN gamma, IL-1, IL-23, and iNOS; (ii) reeducate
the DC and CD4 + T cells; and (iii) activate CD8 + T cells and,
as a result, promote an immune response against the tumor and
prevent tumor progression. In contrast, M2 macrophages and
TAM increase angiogenesis and formation of tumor-associated
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fibroblasts. These cells attenuate immune responses in the TME
and increase tumor progression (104–107).
Various agents that participate in the interaction between
tumor cells and M2 macrophages have been targeted using the
CRISPR/Cas9 system. These targets include: (I) macrophage
Signal Regulatory Protein a (SIRPa). The crosstalk between
SIRP-a on macrophages and CD47 receptors on tumor cells
prevents phagocytosis of cancerous cells via the “Don’t eat
me” signal. Turning off this signaling by knocking out the
SIRP-α using CRISPR/Cas9 enables phagocytosis of cancer cells
(108); (II) Kindlin2, this protein is another therapeutic target
that increases the secretion of Cancer Stimulating Factor1
(CSF1) from tumor cells. Moreover, Kindlin2 induces chemotaxis
of macrophages to the TME, which subsequently constitutes
the dominant population. Ablating Kindlin2 expression using
CRISPR/Cas9 technology inhibited invasion and migration of
tumor cells without affecting their proliferation rate (109);
(III) Osteopontin (OPN) glycophosphoprotein in tumor cells
increases the recruitment of M2 macrophages. Therefore, it has
been targeted in cancer treatment. OPN knockout in tumor
cells by CRISPR/Cas9 decreases the chemotaxis of macrophages
and increases the sensitivity of cancer cells to CD8 + T
cells cytotoxicity (110); (IV) Lysosome Associated Membrane
Protein Type 2A (LAMP2a) is another agent expression which
is increased by tumor cells in TAMs. LAMP2a inactivation
using CRISPR/Cas9 reduces TAM activation and prevents
the suppression of the immune system and decreases tumor
growth (111); (V) IL-8 released by macrophages increases
tumor growth and metastasis. It has been revealed that knock
out of the IL-8 receptor, CXCR2, by CRISPR/Cas9 in triple-
negative breast cancer cell lines reduces the progression of the
tumor (112); and (VI) Tumor-Secreted Protein S (Pros1) is the
best-studied ligand of Tyro3/Axl/Mer (TAM) receptor tyrosine
kinases, and its CRISPR-based deletion inhibits M2 polarization,
leading to heightened immune infiltration and reduced tumor
viability (113).
Theoretically, many other potential targets can affect
macrophage polarization toward the M2 phenotype and their
immunosuppressive features. Therefore, this could be a hot
topic for future investigations not only in treating cancer using
CRISPR technology but also in finding suitable targets for
pharmacological drugs or monoclonal antibodies.
Novel Cellular Immunotherapy via
CRISPR/Cas
Immune cell therapy has emerged as a novel approach
after traditional pharmaceuticals such as small molecules and
biopharmaceuticals, like therapeutic proteins, including mAbs
(114). Due to an extensive TCR repertoire and their ability
to distinguish themselves from non-self-epitopes produced
during tumorigenesis, T lymphocytes play a pivotal role in
tumor surveillance and cancer eradication. Thus, attempts
have been made to produce, guide, or enhance cellular
immunotherapy against cancer over the past decades. T cell-
based immunotherapy is attributed to the implementation of
ex vivo manipulated T lymphocytes aiming to eliminate tumors
with TCR-engineered T lymphocytes and Chimeric Antigen
Receptors T cells (CAR T Cells) as its main strategies (83, 102).
In the former, patient’s T lymphocytes are transfected to express
a transgenic TCR derived from other patients or animal models
with specificity against a Tumor-Associated Antigen (TAA),
and the latter exploits chimeric receptors with their antigen
recognizing domains mostly acquired from antibodies (115).
Universal CAR T Cells Production via CRISPR/Cas
Despite significant breakthroughs in CAR T Cells’ application in
hematologic malignancies elimination, there are still considerable
barriers in the application of CAR T cell therapy, specifically
against solid tumors, and also throughout its laborious
manufacturing process (116). In CAR T cell therapy, T cells
can be derived from patients (autologous) or an allogeneic
donor. Using autologous T cells is a time-consuming process and
largely depends on the quality and quantity of autologous T cells
harvested from the patient. These issues are also coupled with the
expense of manufacturing autologous T cells (117, 118). One of
the substantial barriers in using allogeneic T cells is the presence
of endogenous MHC class I and TCR on donor’s T lymphocytes,
which cause alloreactivity and graft-versus-host disease (GVHD),
respectively. The former is dependent on the TCR repertoire of
the recipient (119, 120).
To overcome the aforementioned HLA barriers in the
implementation of third-party donors-derived T lymphocytes,
Poirot et al. were first able to knock out endogenous TCR by
TALEN-mediated disruption of T cell receptor alpha constant
chain (TRAC) in lentiviral-transduced CD19 CAR T cells
(121). This platform was further entered into clinical studies
on two infants with relapsed refractory CD19 + B cell ALL
(122). “Universal CAR T cells” are now being manufactured
by knocking out TCR and HLA-I in allogeneic T cells (123).
Furthermore, Eyquem et al. have exploited CRISPR/Cas9 to
insert the CAR gene and remove the TCR gene concurrently by
introducing the CAR gene into the TRAC locus. They observed
a regular CAR expression in T cells, increased potency of T
cells, and decreased terminal differentiation and exhaustion in
the mouse model of AML (124).
CRISPR/Cas9 technology was further used to couple allogenic
CAR T cells and checkpoint pathway disruption. In a study by
Ren et al. CRISPR/Cas9 technology was employed to knock out
PDCD1, TRAC, and beta-2-microglobulin (β2M), which encodes
the accessory chain of MHC class I in CD19 or PSCA CAR T
cells. These T cells exhibited robust antitumor activity and did
not induce GVHD in the leukemia mice model (125). In a similar
study on EGFRvIII-targeted CAR T cells and their triple gene-
edited CAR, T cells displayed an enhanced profile in preclinical
glioblastoma models (126).
Of T cell-based immunotherapies, the necessity of TCR
knockout is not confined to CAR T cell therapy. In TCR-
engineered T cells, the α and β chains of endogenous TCR
are shown to pair with the transgenic TCR α and β chains.
This mispairing disrupts efficient T cell redirection toward the
targeted antigen and also poses the risk of novel autoreactivity.
Moreover, competition of these four chains for binding to the
CD3 complex hampers the translocation and, consequently,
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the sufficient display of transgenic TCR on the cell surface.
These are among the culprits underlying the poor performance
of TCR-engineered T cells in clinical studies (127, 128). In a
pioneering study by Provasi et al., ZFNs were designed to obstruct
endogenous TCR β and α chain genes expression and a higher
level of cell surface exogenous TCR display alongside superior
specificity was reported (129). CRISPR/Cas-mediated disruption
of surface TCR expression in TCR-engineered T cells has paved
its way into clinical studies, and will be discussed in the following
sections (130).
Immune Checkpoint Inhibition via CRISPR/Cas
Engineered T cells’ activity is susceptible to be impeded via
natural immune checkpoint regulators. Thus, identification of
these immune checkpoint regulators, such as programmed
cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4), and other inhibitory signaling, has created a
new vision for cancer immunotherapy (131, 132). Overexpression
of immune checkpoint regulators and up-regulation of their
cognate inhibitory ligands (e.g., PDL1 and CTLA4 ligand) in
the TME may limit TCR-engineered and CAR T cell persistence
and function. Accordingly, this will lead to impaired clinical
outcomes of this strategy (15). The CRISPR/Cas9-based editing
could be used to ablate PD-1 and CTLA-4 in order to increase the
efficiency of T cell-based immunotherapy (125).
Gene knock-out of PD-1 in Car T cells using CRISPR
technology was first applied by Su et al., and resulted in enhanced
cytotoxicity without affecting T cells viability (133). Since then,
several groups reported similar results while administering
different methods. Hu et al. used CRISPR/Cas9 against the
PDCD1 gene, accompanied by anti CD133 CAR insertion
into the genome using the piggyback transposon system. They
reported increased T cell proliferation and cytokine secretion
(134). In another study, a ground-breaking one-step system
named knock-in and immune-checkpoint knockout (KIKO
CAR-T cell) was developed, which relied on the cpfl system
to mediate simultaneous knock-in of two different CARs and
knockout of PD-1 and TRAC. Elevated cytokine production
and cytotoxicity and decreased levels of exhaustion markers
were reported (135). PD-1 knockout CAR T cells were also
assessed against glioblastoma, hepatocellular, and K562 tumor
cell lines and demonstrated enhanced anti-tumor activity,
reduced exhaustion, and augmented killing power in Car T cells
(136–138). CRISPR/Cas9-mediated PD-1 knockout in T cells is
now under clinical evaluation in a phase one trial on metastatic
non-small-cell lung cancer (139).
Zhang et al. successfully generated lymphocyte activating
gene-3 (LAG-3) knock-out CAR T cells using CRISPR/Cas9.
They reported no significant viability or immunophenotypic
changes in cultured CAR T cells in vitro. However, LAG-3
knockout CAR T cells possessed more vigorous antigen-specific
anti-tumor activity in a xenograft mouse model (140).
The Fas receptor CD95 binds to its ligand, which is
overexpressed on tumor cells and induces T cells’ apoptosis and
loss of function (141). In order to increase resistance to Fas-
mediated apoptosis, Ren and colleagues generated allogeneic
universal CAR T cells via double knockout of endogenous
TCR and HLA class I (HLA-I). Afterward, they disrupted the
Fas receptor, PD1, and CTLA-4 in the same way and finally
accomplished quadruple gene disruption in T cells with the
one-shot system. Also, generating universal allogeneic T cells
with multiple negative regulators (i.e., PD-1 and CD95/Fas death
receptor) knocked out has been demonstrated (142).
CAR T Cell Functionality Augmentation via
CRISPR/Cas
Using CRISPR/Cas9 to knock out the Granulocyte-Macrophage
Colony Stimulating Factor (GM-CSF) gene in CAR T cells
increased their antitumor activity and survival. Knocking out the
GM-CSF gene not only increased CAR T cell activity but also
decreased neuroinflammation and the probability of CRS (143).
It is known that CD7 targeting CAR T cells can destroy
each other by targeting CD7 markers present on themselves,
an action termed fratricidal activity. Silva et al. indicated that
knocking out CD7 in CAR T cells using CRISPR/Cas9 prevents
fratricidal activity followed by CAR T cell immunotherapies
(144). Moreover, knocking out CD7 and TRAC in CAR T
cells increased the efficacy in the treatment of T cell acute
lymphoblastic leukemia (T ALL) (145).
Jung et al. used CRISPR/Cas9 to knock out Diacylglycerol
Kinase (DGK) in CAR T cells. DGK is an enzyme that metabolizes
diacylglycerol to phosphatidic acid (PA), knocking out the DGK
gene increases CD3 signaling and improves T cell function by
boosting TCR signaling (146).
Studies have confirmed that knocking down TET2, a tumor
suppressor gene, leads to epigenetic and phenotypic alterations
in T cells, which can improve clinical results (147). Fraietta
et al. showed that using CRISPR/Cas9 to knock out the CD19
CAR gene into the TET2 locus promotes anti CD19 CAR T cell
activity (147).
CRISPR/Cas and Oncolytic Virotherapy
Oncolytic viruses (OVs) possess a higher tendency to infect
and replicate within cancerous cells than normal cells. Based
on the promise of naturally occurring OVs, their further
genetic manipulation has turned into an up-and-coming strategy
(148). These manipulations mainly focus on increasing their
tumor-selectivity, tumor tropism, and therapeutic efficacy and
decreasing their off-tumor toxicity and pathogenicity against
non-neoplastic cells. They mainly stem from the normal cells’
ability to develop intracellular anti-virus defense mechanisms
which are mostly accompanied by the host cell’s apoptosis. In
neoplastic cells, on the other hand, anti-apoptotic molecules
are overexpressed and programmed cell death is obscured.
Hence, the anti-virus immune-compromised cells turn into
a suitable place for OVs to replicate and subsequently to
burst the cell itself and to spread viral particles’ locally
among other cancerous cells (149, 150). The first and only
OV to attain FDA approval is T-VEC (IMLYGIC R©) with
an indication for advanced melanoma (151). T-VCE is an
attenuated Herpes Simplex Virus 1 (HSV-1) with decreased
pathogenicity and increased tumor selectivity. It is also
engineered to release GM-CSF and to enhance MHC-mediated
antigen presentation (151). The potential of OV in cancer
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therapy and its genetic manipulation by strategies except
CRISPR/Cas have been extensively reviewed elsewhere (152–
155). Here, the focus is on the application of CRISPR/Cas in
oncolytic virotherapy.
Genetic manipulation of OVs with large genomes, such
as HSV, Adenovirus (Adv), and Vaccinia Virus (VACV), by
traditional techniques is laborious and has low efficiency.
CRISPR/Cas, on the other hand, expedites recombinant OV
generation. It simplifies the process of deletion and insertion
compared to the traditional strategies (156).
To achieve tumor selectivity and oncolytic efficacy, HSV-
1 genes have been repeatedly subject to CRISPR/Cas-mediated
knockout both through NHEJ (156) and HDR-mediated
replacement with foreign genes (156–158). CRISPR/Cas has
also been able to mediate multiple knockouts in HSV-1 (158).
Various approaches have been implemented to further enhance
the knockout efficiency, including enrichment via selectable
markers, and also the incorporation of Scr7, an NHEJ inhibitor,
to enhance HDR/NHEJ ratio in HSV-1 (157, 158). Collectively, all
of these studies revealed low off-target activity of the CRISPR/Cas
platform (156–158). HDR-mediated knock-in has demonstrated
to be feasible and more efficient relative to mere homologous
recombination in HSV-1 in several studies (156–158).
VACV is another OV with great therapeutic potential
with numerous complete and undergoing clinical trials (159).
CRISPR/Cas brought about simultaneous knockout of viral N1L,
which plays a pivotal role in VACV virulence and host immune
response modulation to VACV and TRP2, which is a TAA, inside
the N1L locus (160). Theoretically, delivery of TRP2 to the tumor
and induction of adaptive immune response can promote VACV
into a cancer therapeutic viral vaccine. CRISPR/Cas-mediated
simultaneous double knockout of two immune-regulatory genes,
N1L and A46R, has also been reported and is presumed to
enhance VACV immune response induction. Accordingly, it can
be concluded that sgRNA-guided Cas9 can concomitantly target
multiple sites on the VACV genome (160).
CRISPR/Cas system was used to exert indels into the
EGFP gene in a recombinant adenoviral vector. The mutations’
inheritance to the next generations alongside its safety in terms
of off-tumor activity were observed as well (156).
Plus, the CRISPR/Cas platform can be utilized to equip OVs
with immune-stimulants or anti-tumoral agents. In a study by
Cai and colleagues, oncolytic Human Simplex Virus 2 (oHSV-2)
was armed with murine IL-15 via CRISPR/Cas9. The continuous
intra-tumoral expression of IL-15 enhanced T cells anti-tumor
response and also reduced the tumor mass. Incorporation of
immune-modulators within the genome of OVs obviates the need
for their systematic administration. Due to the local release of the
immune-stimulants, this strategy subsequently reduces the risk of
systematic side effects (161).
In addition, OVs can join their gene therapy delivery
potential and their intrinsic anti-tumor activity to elicit a
synergistic therapeutic response. Following the primary finding
that CRISPR/Cas-mediated RAS knockout results in tumor
regression in Rhabdomyosarcoma, Phelps and colleagues
developed a CRISPR/Cas-harboring recombinant Myxoma
Virus. This OV carried a spCas9-2A-Csy4 cassette followed
by two NRAS-targeting sgRNAs. Csy4 ribonuclease was
incorporated to split the sgRNAs from the 3’ end of mRNA
molecules. A significant although not sustainable reduction in
xenograft tumor growth was reported and further enhancing the
tumor-specificity of this OV is recommended (162).
CRISPR/Cas IN CANCER CLINICAL
TRIALS
In early 2018, the University of Pennsylvania, in collaboration
with Tmunity, launched the first-in-human phase 1 CRISPR gene
editing trial on NY-ESO-1 targeting TCR-engineered T cells in
melanoma and myeloma patients. These T cells lacked TRAC,
TRBC, and PDCD1 genes expression through CRISPR/Cas9-
mediated editing. This study confirmed the safety of multiplex
CRISPR-Cas9 editing of the human genome since neither of
the subjects displayed cytokine release syndrome (CRS) or other
side effects. Additionally, no rejection of transferred T cells due
to pre-existing immunity against Cas9 among individuals was
observed, further approving the potential of this technology in
cancer treatment (130).
While Allogene Therapeutics and Cellectis utilize TALEN
to produce TCR and MHC knockout universal CARs in their
clinical trials (NCT04093596, NCT04106076, NCT03190278 to
name a few), in July 2019, CRISPR Therapeutics initiated its first
clinical trial evaluating CTX110 (NCT04035434). CTX110 are
universal CD19-directed CAR T cells developed through using
CRISPR/Cas9 to insert CAR into the TRAC locus, resulting in
endogenous TCR disruption and also knockout of B2M and thus
MHC1 for Refractory/Relapsed B cell malignancies.
In a clinical trial by Baylor College of Medicine
(NCT03690011), T cells underwent endogenous CD7 knockout
through CRISPR/Cas9 technology prior to receiving CD7-
targeting CARs in order to avoid fratricidal activity. This study,
which is designed for high-risk T-cell malignancies, is yet to
recruit patients.
The Clinical application of the CRISPR/Cas9 platform is
not confined to engineering cellular-based therapeutics. In a
study initiated in mid-2018 (NCT03606486), the University
of Washington developed a minimally invasive test to
detect ovarian cancer through screening cervix pap smear
samples for tumor-associated mutations in TP53 (i.e., the
most common mutated gene in ovarian cancer). The team
employed CRISPR-Duplex sequencing, which combines ultra-
accurate Duplex Sequencing with CRISPR/Cas9 excision of
target regions, leading to enrichment through size selection
before sequencing library preparation (163). In another study in
the Children’s Research Institute (NCT03332030), an induced
Pluripotent Stem Cell (iPSC) bank was established for patients
with Neurofibromatosis type 1 (NF1) phenotype. After that,
CRISPR/Cas9 technology was utilized to develop isogenic NF1
wild-type (NF1 + / +), NF1 heterozygous (NF1 ± ), and NF1
homozygous (NF1-/-) iPSC lines from individual patients. These
iPSC lines are then differentiated to central nervous system
tumor-relevant cells. They are screened to identify the drugs that
have the potential to reverse or alleviate the disease phenotypes.
Frontiers in Immunology | www.frontiersin.org 11 September 2020 | Volume 11 | Article 2062
fimmu-11-02062 September 25, 2020 Time: 20:3 # 12
Azangou-Khyavy et al. CRISPR/Cas Application in Cancer Treatment
FIGURE 4 | Some strategies to solve CRISPR system limitations. (a) Systems that need dimerization to cleave both strands: 1. dCas-FOK1 2. nCas9. (b) Cas9
variants’ activity can be switched on and off by cell-permeable molecules: (1) Intein-Cas9 is activated by excision of the intein bound to a specific position in Cas9.
A cell-permeable small molecule induces this excision (189, 211). (2) Split-Cas9 is a Cas9 molecule that has been split into two fragments, and these two can be
dimerized via drug-binding dimerization domains and a cell-permeable drug (212). (3) Degron-Cas9 is formed by binding a destabilizing domain (degron) to Cas9
protein. Previous studies have introduced a different type of degron that can bind to the protein of interest and decrease the stability of that protein in the presence or
absence of specific small molecules. Degron domains can also be fused to the RBP-effector complex to regulate its stability and activity of the CRISPR system as a
result (190, 213–216).
CRISPR: LIMITATIONS TO SOLVE
CRISPR immune-related adverse effects pose constraints in its
therapeutic applications. The delivery system, Cas protein, and
sgRNA can all evoke the host innate and acquired immune
system. Pre-existing antibodies against SaCas9 and SpCas9 were
found in 78 and 58% of donors, respectively. Likewise, anti-
SaCas9 and anti-SpCas9 T cells were found in 78 and 67% of
donors (164). Furthermore, pattern recognition receptors might
recognize the secondary structure of sgRNAs and initiate an
immune response (78). Further studies are required to ascertain
whether or not these immune reactions could restrict the clinical
potential of this platform (4).
The CRISPR/Cas9 system creates double-strand breaks in
the genome, which can induce p53-mediated apoptosis in
transfected cells and reduce cell viability. Wildtype p53 cells
may die, whereas mutant p53 cells can be selected as a
result of Darwinian selection-like evolution. Therefore, P53
inhibition can improve the efficacy of genome editing. In
order to reduce the risk concerning p53 mutation in cells in
cell replacement therapies, p53 function should be monitored
(165, 166).
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At the CRISPR target site, significant on-target mutagenesis,
such as deletions and genomic rearrangements, were reported,
which may have pathogenic effects (167). Incorporating gene
encoding chimeric suicide receptors alongside the platform can
induce drug-dependent apoptosis. These receptors bind to a drug
by their extracellular domain and use a caspase9 endodomain as
an effector (168). This strategy and similar common strategies in
CAR T cell therapy using the suicide gene increases safety in using
CRISPR mediated genome-edited cells in case of unpredicted
adverse effects (169).
Off-target effects (OTEs) are still the primary limiting concern
in the application of genome editing in clinical trials (170).
Designing appropriate gRNA, selecting more specific nucleases,
and restricting the exposure time to active nucleases are three
primary strategies in reducing OTEs.
Appropriate gRNA design can significantly reduce OTEs and
many gRNA design software tools that predict the probability
of off-target cutting, such as elevation, azimuth, and benching
(171). Truncating 5′ end of gRNAs and chemical modification of
crRNA sites for impairing hybridization to off-target sequences
are possible changes implicated in gRNA that improve specificity
(172, 173).
The choice of nuclease is another famous gate through which
enhanced specificity can be achieved. Cpf1 and fnCas9 have
been reported to have higher specificity than SpCas9 (174, 175).
Changing amino acid residues for reducing OTEs has led to
engineering high fidelity Cas9 proteins such as SpCas9-HF1,
eSpCas9, and HypaCas9. The mechanism of action of these
altered Cas9 proteins might be a change in nuclease domain
activation pattern (HNH domain) or change in the strength of
binding to target DNA (176–178). In an attempt to construct
a SpCas9 that can recognize a broad range of PAM sequences,
several Cas proteins with reduced OTEs were created (179, 180).
Another form of nucleases was developed by fusing dCas to the
FOK1 cleavage domain that generates a chimeric protein that
needs dimerization for DNA cleavage. Since two closely located
sequences’ recognition is needed through two distinct sgRNAs,
this approach theoretically increases specificity (181). There is a
similar strategy using nickase Cas9 that has a mutation in one of
two nuclease domains of Cas9 protein. As a result, each nCas9,
which is guided with a separate sgRNA, cleaves only one strand
of DNA (Figure 4A) (182).
Limiting exposure time to CRISPR nuclease is the third
primary strategy for reducing OTEs, which may have a
concomitant reduction in on-target efficacy (171). Integrase-
deficient lentiviral vector, ribonucleoprotein (RNP) complexes,
and Cas9 mRNA are all delivery systems generated for shortening
Cas9 exposure (183–185). Despite the many advantages of using
the RNP delivery system, immune adverse events must be noted
(186). Other strategies to limit this exposure time are: (i) using
doxycycline-inducible promoter controlling Cas9 expression in
order to have a regulated expression; (ii) creating Cas9-intein,
Cas9-degron, and split Cas to regulate Cas9 activity through
cell-permeable compounds (Figure 4B); (iii) designing a self-
restriction construct consisting of a Cas9 that targets the system’s
gRNA; and (iv) using a Cas9 natural inhibitor (e.g., AcrIIA4)
(187–193).
DISCUSSION AND FUTURE PROSPECTS
CRISPR/Cas9 has driven a paradigm shift in cancer treatment
approaches since the day it was introduced. As mentioned
above, despite sublime influences given by the CRISPR/Cas9
system in gene therapy, there are still many challenges that have
to be considered.
The alternative Cas13 has been developed regarding the
acknowledged challenges of Cas9-based CRISPR systems,
including the risk of off-target toxicity, affecting wild type
transcripts, and high molecular weight. Cas13 binds and cleaves
single-stranded RNAs rather than DNA; therefore, it reduces the
risk of off-target toxicity and wild type transcripts alterations.
Moreover, the Cas13d subtype is known to maintain one of
the lowest molecular weights among Cas enzymes. Thus, it
can be introduced in target cells more easily through viral
vectors. In conclusion, these RNA-targeting Cas enzymes
would result in a considerable apprehension over transcriptome
and RNA regulators functions in cancer cells (194). Besides,
many types of other CRISPR related nucleases have been
introduced, including Cpf1 and fnCas9 and nucleases that
were made by changing amino acid residues in SpCas9
(SpCas9-HF1, eSpCas9, and HypaCas9) (174, 175). Application
of these nucleases in cancer treatment and their probable
advantages over more-studied SpCas9 should instead be
evaluated in future studies.
Recent innovations in CRISPR-based systems have led to the
emergence of new promising applications in cancer therapies.
For instance, CDetection, as a CRISPR/Cas12b-based DNA
detection system, has been developed to ease precise and sensitive
DNA detection. Genetic variations, including Single Nucleotide
Polymorphisms (SNPs), are also considered as cancer (especially
sporadic cancers) etiologies (195, 196). Since the association of
various SNPs with different cancers is well-established, precise
DNA detection and its application in SNP genotyping would
be favorable in the early clinical diagnosis of primary cancers.
This precise DNA detection system is estimated to be able
to detect over 20,000 known human disease-associated point
mutations (197).
In summary, CRISPR and the above-mentioned advantages
over other genome editing techniques could pave the road
for cancer treatment in the future. This objective could be
accomplished via using CRISPR as a potent instrument for
gene therapy and identification of prognostic and predictive
biomarkers, novel signaling pathways and targets, and new drugs
in cancer treatment. CRISPR could also be used in identifying
novel immune system-tumor interplays and augmenting cellular
immunotherapies; however, related limitations and cautions
should be noted before any interventions.
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